Profile of action of diuretics;DAS WIRKPROFIL VON DIURETIKA

Nieren- und Hochdruckkrankheiten

Volumn 25, Issue 4, 1996, Pages 162-170

  Knauf, H ^a   Mutschler, E ^a  

^a St Bernward Krankenhaus ^*  (Germany)

Author keywords

antikaliuretics; direct and postdiuretic effects; diuretic effectiveness; duration of action; loop diuretics; pattern of electrolyte excretion; thiazides

Indexed keywords

ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; CALCIUM ION; DIURETIC AGENT; LOOP DIURETIC AGENT; MAGNESIUM ION; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADRENERGIC SYSTEM; ARTICLE; CALCIUM EXCRETION; DIURESIS; DIURETIC ACTIVITY; DRUG EFFICACY; ELECTROLYTE EXCRETION; ELECTROLYTE URINE LEVEL; KALIURESIS; KIDNEY BLOOD FLOW; MAGNESIUM EXCRETION; NATRIURESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0029887546     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Brater D.C.: Clinical pharmcology of loop diuretics. Drugs 41 (Suppl. 3), 14-22 (1991).
2. Brater D.C., P. Chennavasin, R. Seiwell: Furosemide in patients with heart failure: Shift in dose-response curves. Clin. Pharmacol. Ther. 28, 182-186 (1980).
3. Brater D.C., S.A. Anderson, D. Brown-Cartwright: Response to furosemide in chronic renal insufficiency: Rationale for limited dose. Clin. Pharmacol. Ther. 40, 134-139 (1986).
4. Diehm C., H. Mörl: Long-term safety with piretanide therapy. In: Britton K.E.: Piretanide - a new antihypertensive diuretic. Excerpta Medica, Amsterdam 1985, 29-34.
5. Dols W., J. Freude, M. Verho, B. Rangoonwala: A double-blind study of piretanide in the treatment of hypertension. Curr. Med. Res. Opin. 8, 649-658 (1983).
6. Gerber J.G.: Antihypertensive agents and diuretics. In: Anderson R.J., R.W. Schrier: Clinical use of drugs in patients with kidney and liver disease. Saunders, London 1981, 211-229.
7. Hasenfuß G., C. Holubarsch, C. Herzog, H. Knauf, H. Spahn, E. Mutschler, H. Just: Influence of cardiac function on the diuretic and hemodynamic effects of the loop diuretic piretanide. Clin. Cardiol. 10, 83-88 (1987).
8. Heath W.C., E.D. Freis: Triamterene with hydrochlorothiazide in the treatment of hypertension. JAMA 186, 119-122 (1963).
9. Hollifield J.W.: Thiazide treatment of hypertension. Effects of thiazide diuretics on serum potassium, magnesium and ventricular ectopy. Am. J. Med. 80 (Suppl. 4A), 8-12 (1986).
10. Kaplan N.M.: Diuretics versus other agents in the therapy of primary (essential) hypertension. In: Puschett J.B., A. Greenberg: Diuretics III, chemistry, pharmacology, and clinical applications. Elsevier, Amsterdam 1990, 407-410.
11. Keller E., G. Hoppe-Seyler, P. Schollmeyer: Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur. J. Clin. Pharmacol. 20, 27-33 (1981).
12. Keller E., G. Hoppe-Seyler, R. Mumm, P. Schollmeyer: Disposition and diuretic effect of furosemide in the nephrotic syndrome. Clin. Pharmacol. Ther. 32, 442-449 (1982).
13. Knauf H.: The role of low-dose diuretics in essential hypertension. J. Cardiovasc. Pharmacol. 22 (Suppl. 6), 1-7 (1993).
14. Knauf H., E. Mutschler: Pharmacodynamics and pharmacokinetics of xipamide in patients with normal and impaired kidney function. Eur. J. Clin. Pharmacol. 26, 687-693 (1984).
15. Knauf H., E. Mutschler: Saluretic effects of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion. Eur. J. Clin. Pharmacol. 39, 337-343 (1990).
16. Knauf H., E. Mutschler: Pharmacodynamic and pharmacokinetic considerations on diuretics as a basis of differential therapy. Klin. Wschr. 69, 239-250 (1991).
17. Knauf H., E. Mutschler: Low-dose segmental blockade of the nephron rather than high-dose diuretic monotherapy. Eur. J. Clin. Pharmacol. 44 (Suppl. 1), 63-68 (1993).
18. + loss during 24 hours. Eur. J. Clin. Pharmacol. 43, 23-27 (1992).
19. Knauf H., E. Mutschler: Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J. Cardiovasc. Pharmacol. 26, 394-400 (1995).
20. Knauf H., K. Reuter, E. Mutschler: Limitation on the use of amiloride in early renal failure. Eur. J. Clin. Pharmacol. 28, 61-66 (1985).
21. Knauf H., W. Cawello, G. Schmidt, E. Mutschler: The saluretic effect of the thiazide-diuretic bemetizide in relation to the glomerular filtration rate. Eur. J. Clin. Pharmacol. 46, 9-13 (1994).
22. Knauf H., R. Liebig, P. Schollmeyer, J. Rosenthal, E.U. Kölle, E. Mutschler: Pharmacodynamics and pharmacokinetics of etozolin/ozolinone in hypertensive patients with normal and impaired kidney function. Eur. J. Clin. Pharmacol. 26, 687-693 (1984).
23. Multicenter Diuretic Study: Multiclinic comparison of amiloride, hydrochlorothiazide, and hydrochlorothiazide plus amiloride in essential hypertension. Arch. Intern. Med. 141, 482-486 (1981).
24. Skorecki K.L., D.M. Brenner: Body fluid homeostasis in congestive heart failure and cirrhosis with ascites. Am. J. Med. 72, 323-338 (1982).
25. Schrier R.W.: Pathogenesis of sodium and water retention in high and low output cardiac failure, cirrhosis, nephrotic syndrome, and pregnancy. N. Engl. J. Med. 319, 1065-1072 (1988).
26. Schrier R.W., V. Arroyo, M. Bernadi, M. Epstein, J.H. Henriksen, J. Rodes: Peripheral arterial vasodilation hypothesis: a proposal for the initation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151-1157 (1988).
27. Tannenbaum P.J., A.P. Crosley: A comparison of the effects of hydrochlorothiazide and hydrochlorothiazide in combination with triamterene on electrolyte balance. Clin. Pharmacol. Ther. 7, 777-782 (1966).
28. Tartagni F., F. Tomassini, V. Cervi, A.M. Bargossi, O. Cappelletti, B. Magnani: Metabolic effects of long-term piretanide use. Curr. Ther. Res. 39, 1004-1010 (1986).
29. Wilcox C.S.: Diuretics. In: Brenner B.M., F.C. Rector: The kidney. Saunders, Philadelphia 1991, 2123-2147.